Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Kiadis Pharma

Kiadis Pharma

Kiadis Pharma is a biotechnology company developing stem cell regenerative medicine treatments for blood cancers and blood disorders.

Kiadis Pharma is a company that looks to provide options for stem cell transplant operations in blood cancer patients. The company was founded in 1997, in Amsterdam, Noord-Holland, The Netherlands.

The company is interested in creating solutions for patients that have complications and limitations due to blood cancer. They have created and developed three blood cancer products that are in clinical development that are meant to provide treatment options for terminal cancer patients.

Kladis Pharma is developing cancer immunotherapeutics as well as novel adjunctive treatments. In their pipeline they have an NK-cell Therapies for HSCT in blood cancer, AAML R/R, multiple myeloma, respiratory and COVID-19 diseases, and other cancers and infections. Their pipeline treatments are in phases one and two, as well as in proof-of-concept.

Their NK-cell Therapies (Natural Killer) are designed to assist the immune system's natural ability to detect, identify, and fight against diseases and malignant cancer cells.

Timeline

1997
Kiadis Pharma was founded.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Kiadis Pharma

Web

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
July 27, 2021
FierceBiotech
As SynOx Therapeutics gears up to test its anti-CSF1R antibody in registrational trials, the Dublin-based biotech is getting a pair of new leaders. Ray Barlow, formerly the chief business officer of Kiadis Pharma, signs on as CEO and Ton Logtenberg, Ph.D. becomes the company's new non-executive chairman.
BioSpace
November 12, 2020
BioSpace
Pluristyx, Inc., a leading chemistry, manufacturing, and controls (CMC), consulting, process development, and tools provider for cell and gene therapy companies, today announced it will be supporting a collaboration between Kiadis Pharma (Kiadis), and the Advanced Regenerative Manufacturing Institute's (ARMI) BioFabUSA program working on Kiadis' COVID-19 research and development program
Nick Paul
July 8, 2020
FierceBiotech
Sanofi has licensed natural killer cells from Kiadis Pharma to use in combination with its multiple myeloma drug Sarclisa. The backloaded, €875 million ($986 million) deal gives Sanofi global rights to therapies that could mitigate an efficacy-limiting shortcoming of anti-CD38 antibodies.

References

Golden logo
By using this site, you agree to our Terms & Conditions.